Arcutis Biotherapeutics Inc Congressional Trading
According to U.S. congressional financial disclosures filed under the STOCK Act, members of Congress have reported 6 trades in Arcutis Biotherapeutics Inc (NASDAQ: ARQT) since 2022, across 2 members, worth an estimated $48.00K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts). 4 buys against 2 sells, a modestly buy-led skew, with Democratic members responsible for 100% of the trades and Republican members 0%. The most recent disclosure shown was filed June 2026, and Gilbert Cisneros has filed the most ARQT transactions among those shown, with 3. One notable disclosed move was a purchase by Gilbert Cisneros on May 29, 2026, up 15.8% since. These figures are drawn from public House and Senate periodic transaction reports and reflect what members were required to disclose, not the current market value of any position. Arcutis Biotherapeutics Inc's current Quantellect Tide Score is 39 out of 100 (Calm Tide), Bottom 30% of universe (3876); the Tide Score is generated algorithmically from public filings and market data and is not investment advice. For the full record, including the month-by-month buy and sell timeline, the party breakdown, top buyers and sellers, and every individual filing, see the Arcutis Biotherapeutics Inc (ARQT) stock overview and the complete trade table below.
Data updated
Price & congressional trade timeline
Party breakdown
Arcutis Biotherapeutics congressional trading activity
| Politician | Published | Traded | Filed After | Type | Size | Return | Owner | |
|---|---|---|---|---|---|---|---|---|
 Gilbert Cisneros House | Jun 8, 2026 | May 29, 2026 | 10 days | BUY |  $1,001 - $15,000 | +15.84% | Self | |
Gilbert Cisneros House | Apr 7, 2026 | Mar 3, 2026 | 35 days | BUY | $1,001 - $15,000 | +5.34% | Self | |
Gilbert Cisneros House | Jan 12, 2026 | Dec 11, 2025 | 32 days | SELL | $1,001 - $15,000 | -15.64% | Self |
Arcutis Biotherapeutics (ARQT) congressional trading FAQ
Can members of Congress legally trade Arcutis Biotherapeutics (ARQT) stock?
Yes. Members of Congress are permitted to trade individual stocks, including Arcutis Biotherapeutics (ARQT), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; it does not imply any trade was improper.
Are congressional Arcutis Biotherapeutics (ARQT) trades public?
Yes. Every congressional trade in Arcutis Biotherapeutics (ARQT) on this page comes from mandatory public STOCK Act disclosure filings, which are filed with a delay and may be revised.
How many times has Congress traded Arcutis Biotherapeutics (ARQT)?
Members of Congress have disclosed 6 trades in Arcutis Biotherapeutics (ARQT) worth $48.00K across 2 members, according to public STOCK Act filings.
Which members of Congress have traded Arcutis Biotherapeutics (ARQT)?
Recent and active filers of Arcutis Biotherapeutics (ARQT) disclosures include Gilbert Cisneros. The full member-by-member trade list is on this page.
Do Democrats or Republicans trade Arcutis Biotherapeutics (ARQT) more?
Across disclosed Arcutis Biotherapeutics (ARQT) trades, 100% were by Democrats and 0% by Republicans, led by Democrats (100%).
What is the most recent congressional Arcutis Biotherapeutics (ARQT) trade?
The most recent disclosed Arcutis Biotherapeutics (ARQT) trade was a purchase by Gilbert Cisneros, filed Jun 7, 2026.
What is Arcutis Biotherapeutics (ARQT)'s Tide Score?
Arcutis Biotherapeutics (ARQT) has a Quantellect Tide Score of 39 (Calm Tide). The Tide Score is a 0-100 read blending price forecast, smart-money flow, technicals, and social sentiment; higher is more bullish.
Browse all stocks Congress tradesCongressional trading overviewArcutis Biotherapeutics (ARQT) stock overview
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. The Tide Score and other figures are generated algorithmically from public filings and market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.